BRKR vs HYPR
BRKR: Bruker is a global leader in high-performance analytical instrumentation and diagnostic solutions for life sciences and materials research, enabling structural biology, drug discovery, and scientific innovation at molecular levels. HYPR: Hyperfine makes AI-powered portable ultra-low-field MRI systems designed to bring affordable brain imaging to hospitals and clinics anywhere, without specialized facilities or technicians.
Side-by-side fundamentals
| Metric | BRKR | HYPR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $60.05 | $0.961 | |
| Market cap as of 2026-07-31 | $9.7B | $88M | |
| PEG as of 2026-07-31 | 1.67 | n/a | |
| Net margin as of 2026-07-31 | -0.3% | -226.9% | BRKR higher |
| Gross margin as of 2026-07-31 | +46.7% | +51.2% | HYPR higher |
| Operating margin as of 2026-07-31 | +0.8% | -226.6% | BRKR higher |
| ROE as of 2026-07-31 | -0.5% | -101.3% | BRKR higher |
| ROA as of 2026-07-31 | -0.2% | -68.8% | BRKR higher |
| Debt / equity as of 2026-07-31 | 0.68 | 0.38 | HYPR lower |
| Revenue growth (YoY) as of 2026-07-31 | +0.4% | +30.7% | HYPR higher |
| Revenue CAGR (3y) SEC XBRL | +10.7% | +25.8% | HYPR higher |
| Dividend yield as of 2026-07-31 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 1.26 | 1.49 | |
| 1-year return as of 2026-07-27 close | +43.2% | -11.0% | BRKR higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.